The imminent departure of the UK from the European Union, combined with the ever developing global patent landscape, means that there has never been a more critical need to remain up to date with the latest thinking on how best to now effectively secure and protect your patents.
Brought to you by the publisher of Life Sciences Intellectual Property Review, Life Sciences Patent Network EUROPE is the latest conference in the 2019 Patent Network series to bring together an unrivalled audience of intellectual property and licensing heads from established and fledgling pharma and biotech companies, along with private practice attorneys, and service providers.
The conference provides delegates with an invaluable opportunity to gain insight into the sector issues of critical current importance; listen to best-in-class case studies; keep abreast of the likely forward impact of key judgements and political jolts; and network with global patent peers.
Key issues for discussion at this year's conference include:
What steps should IP firms and corporate patent counsel take to prepare for Brexit?
What's the likely impact of Brexit on regulatory divergence?
Will the German constitutional case stop the UPC in its tracks?
Should potential SPC applicants apply early under existing EU rules or wait for new UK rules to come into force?
What's the impact of the UK Supreme Court ruling on the Doctrine of Equivalents?
|Leydig, Voit & Mayer||(not set)|
|MSD (Merck)||Assistant Counsel|
|GE||Associate General Counsel, IP Life Sciences|
|Maucher Jenkins||Associate - Patent Attorney|
|Standards in Laboratory Automation||Board Member|
|Life Sciences Patent Network||Business Relations Associate|
|Eagle Genomics||Chief Executive Officer|
|Eli Lilly and Company||Chief Patent Counsel – International Litigation|
|Outpost Medicine Limited||Chief Scientific Officer|
|Life Sciences Patent Network||Commercial Partnerships Director|
|Life Sciences Patent Network||Deupty Editor|
|Indigena Biodiversity Limited||Director|